RU2009133336A - Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами - Google Patents

Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами Download PDF

Info

Publication number
RU2009133336A
RU2009133336A RU2009133336/04A RU2009133336A RU2009133336A RU 2009133336 A RU2009133336 A RU 2009133336A RU 2009133336/04 A RU2009133336/04 A RU 2009133336/04A RU 2009133336 A RU2009133336 A RU 2009133336A RU 2009133336 A RU2009133336 A RU 2009133336A
Authority
RU
Russia
Prior art keywords
optionally substituted
heteroaryl
heterocyclyl
haloalkyl
aryl
Prior art date
Application number
RU2009133336/04A
Other languages
English (en)
Russian (ru)
Inventor
Шифэн ЛЮ (CA)
Шифэн ЛЮ
Цзяньминь ФУ (CA)
Цзяньминь Фу
Раджендер КАМБОДЖ (CA)
Раджендер Камбодж
Ци ЦЗЯ (CA)
Ци Цзя
Марк ВУД (CA)
Марк ВУД
Султан ЧОВДХУРИ (CA)
Султан ЧОВДХУРИ
Цзяниу СУНЬ (CA)
Цзяниу СУНЬ
Original Assignee
Ксенон Фармасьютикалз Инк. (Ca)
Ксенон Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ксенон Фармасьютикалз Инк. (Ca), Ксенон Фармасьютикалз Инк. filed Critical Ксенон Фармасьютикалз Инк. (Ca)
Publication of RU2009133336A publication Critical patent/RU2009133336A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2009133336/04A 2007-02-05 2008-02-05 Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами RU2009133336A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88825307P 2007-02-05 2007-02-05
US60/888,253 2007-02-05
US91212207P 2007-04-16 2007-04-16
US60/912,122 2007-04-16

Publications (1)

Publication Number Publication Date
RU2009133336A true RU2009133336A (ru) 2011-03-20

Family

ID=39420569

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009133336/04A RU2009133336A (ru) 2007-02-05 2008-02-05 Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами

Country Status (12)

Country Link
US (1) US20080194616A1 (pt-PT)
EP (1) EP2079737A1 (pt-PT)
JP (1) JP2010518026A (pt-PT)
AR (1) AR065194A1 (pt-PT)
AU (1) AU2008213836A1 (pt-PT)
BR (1) BRPI0807351A2 (pt-PT)
CA (1) CA2677493A1 (pt-PT)
CL (1) CL2008000369A1 (pt-PT)
MX (1) MX2009008338A (pt-PT)
RU (1) RU2009133336A (pt-PT)
TW (1) TW200838539A (pt-PT)
WO (1) WO2008097991A1 (pt-PT)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577467A (en) * 2006-12-18 2012-04-27 Cardoz Ab Combination of pemirolast and a statin for use in the treatment of inflammatory disorders
AU2007336077A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
MX2010005769A (es) * 2008-01-11 2010-11-12 Glenmark Pharmaceuticals Sa Derivados de pirimidina fusionados como moduladores del trpv3.
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
ES2395002T3 (es) * 2008-04-07 2013-02-07 Cardoz Ab Nueva combinación para uso en el tratamiento de trastornos inflamatorios
US8119647B2 (en) * 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
CN101628913B (zh) * 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CA2846652C (en) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines as pi3k inhibitors
KR20140091022A (ko) 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
US9567331B2 (en) 2011-11-15 2017-02-14 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EA026393B1 (ru) * 2012-05-22 2017-04-28 Дженентек, Инк. N-замещенные бензамиды и их применение в лечении боли
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
UA120353C2 (uk) * 2013-09-10 2019-11-25 Хромоселл Корпорейшн Модулятори натрієвого каналу для лікування болю і діабету
EA201691085A1 (ru) 2013-11-27 2017-02-28 Дженентек, Инк. Замещенные бензамиды и способы их применения
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
ES2843522T3 (es) 2015-02-27 2021-07-19 Incyte Corp Sales del inhibidor de PI3K y procesos para su preparación
PE20180316A1 (es) * 2015-04-15 2018-02-09 Hoffmann La Roche Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
ES2821049T3 (es) * 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
KR20190078587A (ko) 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
EP3801738A4 (en) * 2018-06-05 2022-02-16 InCarda Therapeutics, Inc. PROCEDURE FOR DIAGNOSIS OF BRUGADA SYNDROME USING AN AEROSOL
CA3161008A1 (en) * 2019-11-25 2021-06-03 Amgen Inc. Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
CN110818709B (zh) * 2019-11-28 2022-09-02 成都大学 一种co2参与下合成嘧啶酮类化合物的方法
CN113292557B (zh) * 2021-05-31 2022-02-11 贵州大学 一种含吲哚单元的吡啶并嘧啶酮类介离子衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63112566A (ja) * 1986-10-28 1988-05-17 Nissan Chem Ind Ltd ピリミジノン誘導体、その製法および殺虫・殺ダニ・殺菌剤
AU2004285452A1 (en) * 2003-10-21 2005-05-12 Merck & Co., Inc. Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
MX2007016270A (es) * 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
ATE517899T1 (de) * 2005-10-04 2011-08-15 Angeletti P Ist Richerche Bio Hiv-integrasehemmer
EP1818058A3 (en) * 2006-02-13 2007-11-07 Astion Pharma A/S Treatment of mmp-mediated dermatological diseases with pemirolast

Also Published As

Publication number Publication date
BRPI0807351A2 (pt) 2014-05-20
MX2009008338A (es) 2009-08-12
EP2079737A1 (en) 2009-07-22
CA2677493A1 (en) 2008-08-14
JP2010518026A (ja) 2010-05-27
CL2008000369A1 (es) 2008-04-18
AR065194A1 (es) 2009-05-20
WO2008097991A1 (en) 2008-08-14
TW200838539A (en) 2008-10-01
US20080194616A1 (en) 2008-08-14
AU2008213836A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
RU2009133336A (ru) Пиридопиримидиноновые соединения, применимые при лечении заболеваний или состояний, опосредуемых натриевыми каналами
JP2010518026A5 (pt-PT)
JP6893271B2 (ja) キナーゼ阻害剤である複素環式アミド
KR102570992B1 (ko) 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
US10941117B2 (en) 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
ES2548135T3 (es) Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
TWI617552B (zh) 用於激酶調節及其適應症之化合物及方法
ES2638850T3 (es) Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos
PT1740584E (pt) Derivado de quinolina fundida e sua utilização
AU2015298378B2 (en) Imidazopyridazine compounds
AU2015365465A1 (en) Amido thiadiazole derivatives as NADPH Oxidase inhibitors
JP2022536540A (ja) アミノピリミジンアミドオートファジー阻害剤およびその使用方法
US20200123147A1 (en) Thiazole compounds useful as prmt5 inhibitors
EA036318B1 (ru) 6-аминопиридин-3-илтиазолы в качестве модуляторов rort
JP2023529884A (ja) コラーゲン１翻訳阻害剤及びその使用方法
US10519110B2 (en) Heterocyclic compound
AU2017324281A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof
JP2022081710A (ja) 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
JPWO2020017569A1 (ja) Ｔ型カルシウムチャネル阻害剤
WO2011030798A1 (ja) ８－オキソジヒドロプリン誘導体
US7795267B2 (en) Bicyclic piperazine compound having TGR23 antagonistic activity
US20230348369A1 (en) Nampt modulators
JP2024502106A (ja) ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用
US20240279215A1 (en) Nampt modulators
JP2005306839A (ja) 二環性ピペラジン化合物およびその用途